抗VEGF药物治疗不同病程湿性年龄相关性黄斑变性的临床疗效分析
|
摘要
目的该次研究主要针对不同病程湿性年龄相关性黄斑变性借助抗VEGF药物进行治疗的具体效果进行分析。方法该次研究按照对比治疗的模式展开,方便选取的病例按照患者病程进行分组,均为苏州吴江区第一人民医院接诊患者,其中54例(共计54只患眼),其患病时间在6月以下,即观察组,另54例(共计54只患眼),其患病时间在6～12月,即对照组。两组患者均为该院在2016年5月—2018年3月所接诊,且均借助抗VEGF治疗,针对疗效间差异加以分析。结果结合对两组患者ETDRS量表评估可知,在用药前两组差异有统计学意义(P<0.05);而在分别用药3月后,观察组视力表为(14.65±1.06)改善情况显著优势对照组(t=12.579,P<0.05);且结合对患者CRT测量可知,观察组减少量(156.56±2.07)μm同样优于对照组(t=17.078,P<0.05)。结论就湿性年龄相关性黄斑变性而言,病变时间在6月以下患者使用抗VEGF恢复更为理想,可帮助其视力得到有效改善,对于提升患者生活质量同样存在有积极意义。
Objective To analyze the specific effect of anti VEGF drugs in treatment of wet age-related macular degeneration in different stages. Methods The cases were divided into groups with 54 cases in each, including the observation group(54 affected eyes) whose prevalence time was below 6 months, and the control group(54 affected eyes) whose prevalence time was 6-12 months, and the patients were convenient selected and diagnosed in our hospital from May 2016 to March2018, and treated with anti-VEGF, and the difference in the curative effect was analyzed. Results The ETDRS scale evaluation showed that there was obvious difference between the two groups before medication(P<0.05); after 3 months of medication, the vision table in the observation group was(14.65±1.06), and the improvement condition in the observation group was obviously better than that in the control group,(t=12.579,P<0.05), and the CRT measurement showed that the decrease volume in the observation group was(156.56±2.07)μm, which was better than that in the control group(t=17.078,P<0.05).Conclusion The recovery effect of anti-VEGF of patients whose lesion time was below 6 months is more ideal, which can help the patients improve the vision effectively, and it is of positive significance to improving the quality of life.
Objective To analyze the specific effect of anti VEGF drugs in treatment of wet age-related macular degeneration in different stages. Methods The cases were divided into groups with 54 cases in each, including the observation group(54 affected eyes) whose prevalence time was below 6 months, and the control group(54 affected eyes) whose prevalence time was 6-12 months, and the patients were convenient selected and diagnosed in our hospital from May 2016 to March2018, and treated with anti-VEGF, and the difference in the curative effect was analyzed. Results The ETDRS scale evaluation showed that there was obvious difference between the two groups before medication(P<0.05); after 3 months of medication, the vision table in the observation group was(14.65±1.06), and the improvement condition in the observation group was obviously better than that in the control group,(t=12.579,P<0.05), and the CRT measurement showed that the decrease volume in the observation group was(156.56±2.07)μm, which was better than that in the control group(t=17.078,P<0.05).Conclusion The recovery effect of anti-VEGF of patients whose lesion time was below 6 months is more ideal, which can help the patients improve the vision effectively, and it is of positive significance to improving the quality of life.
引文
[1]李娟娟,黎铧.玻璃体腔注射雷珠单抗对中心凹下瘢痕化的湿性年龄相关性黄斑变性的疗效及意义[J].中华实验眼科杂志,2017,35(1):42-46.
[2]王常观,柳小珍,马志中,等.小神经胶质细胞对湿性年龄相关性黄斑变性患者脉络膜新生血管膜形成的作用[J].中华眼外伤职业眼病杂志,2018,56(1):18-22.
[3]陈圣文.康柏西普对湿性年龄相关性黄斑变性患者脉络膜厚度及睫状后动脉血流的影响[J].中国老年学杂志,2017,37(17):82.
[4]陈露璐,陈有信.CFH Y402H基因药物遗传学与湿性年龄相关性黄斑变性[J].中华眼科杂志,2017,53(2):81.
[5]罗保华.湿性老年性黄斑变性的中医证型与其抗VEGF治疗敏感性的关系研究[D].广州:广州中医药大学,2016.
[6] Lei FENG, Jiang-hua HU, Jie CHEN,等.抗VEGF药物在多灶性脉络膜炎和湿性老年性黄斑变性中的疗效观察和比较(英文)[J].Journal of Zhejiang University-Science B(Biomedicine&Biotechnology), 2018, 19(4):327-332.
[7]何苗,曹奎.雷珠单抗联合光动力疗法对湿性年龄相关性黄斑变性患者视觉功能、敏感度及血清VEGF含量的影响[J].海南医学院学报,2016,22(17):2066-2068.
[8]汪鹭,彭惠.治疗湿性年龄相关性黄斑变性的抗VEGF药物研究进展[J].国际眼科杂志,2016,16(10):1847-1851.
[9]全玉杰,闫加兴,李丽,等.玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性的临床护理[J].实用临床医药杂志,2016,20(6):129-131.
[10]杨艳,徐新荣.视网膜血管瘤样增生和湿性年龄相关性黄斑病变的鉴别[J].国际眼科杂志,2015,15(9):1560-1562.
[11]张燕,郑瑞莲,王瑞夫.玻璃体腔注射抗血管内皮生长因子治疗湿性年龄相关性黄斑变性的临床效果[J].中国医药导报,2016,13(9):140-143.
[2]王常观,柳小珍,马志中,等.小神经胶质细胞对湿性年龄相关性黄斑变性患者脉络膜新生血管膜形成的作用[J].中华眼外伤职业眼病杂志,2018,56(1):18-22.
[3]陈圣文.康柏西普对湿性年龄相关性黄斑变性患者脉络膜厚度及睫状后动脉血流的影响[J].中国老年学杂志,2017,37(17):82.
[4]陈露璐,陈有信.CFH Y402H基因药物遗传学与湿性年龄相关性黄斑变性[J].中华眼科杂志,2017,53(2):81.
[5]罗保华.湿性老年性黄斑变性的中医证型与其抗VEGF治疗敏感性的关系研究[D].广州:广州中医药大学,2016.
[6] Lei FENG, Jiang-hua HU, Jie CHEN,等.抗VEGF药物在多灶性脉络膜炎和湿性老年性黄斑变性中的疗效观察和比较(英文)[J].Journal of Zhejiang University-Science B(Biomedicine&Biotechnology), 2018, 19(4):327-332.
[7]何苗,曹奎.雷珠单抗联合光动力疗法对湿性年龄相关性黄斑变性患者视觉功能、敏感度及血清VEGF含量的影响[J].海南医学院学报,2016,22(17):2066-2068.
[8]汪鹭,彭惠.治疗湿性年龄相关性黄斑变性的抗VEGF药物研究进展[J].国际眼科杂志,2016,16(10):1847-1851.
[9]全玉杰,闫加兴,李丽,等.玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性的临床护理[J].实用临床医药杂志,2016,20(6):129-131.
[10]杨艳,徐新荣.视网膜血管瘤样增生和湿性年龄相关性黄斑病变的鉴别[J].国际眼科杂志,2015,15(9):1560-1562.
[11]张燕,郑瑞莲,王瑞夫.玻璃体腔注射抗血管内皮生长因子治疗湿性年龄相关性黄斑变性的临床效果[J].中国医药导报,2016,13(9):140-143.